Program
pacibekitug
A development code. Also written as “Pacibekitug”.
Its studies are mostly in Myocardial Infarction, led by Novartis.
Furthest: phase 3, since Nov 9, 20261 company-led study, 1 open or runningNext primary completion: Oct 22, 2030 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 3since Nov 9, 2026 | Nov 9, 2026 | Oct 22, 2030phase 3 · NCT07938411 |
- Named in Novartis’s own pipeline as
PAC001 (pacibekitug)
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2026First study: phase 3 study in Myocardial InfarctionFirst studyNCT07938411 · 10,000 planned
Ahead
- Oct 22, 2030Primary completion: phase 3 study in Myocardial InfarctionNCT07938411
TargetBeta
IL6 →read by rule
“Interleukin-6 inhibitor”ChEMBL 37, by rule
Other programs on IL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olokizumabrule | R-Pharm | phase 3 | 19 |
| ziltivekimabrule | Novo Nordisk | phase 3 | 12 |
| clazakizumab | CSL | phase 3 | 10 |
| isomyosaminerule | tnf-pharmaceuticals-inc | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07938411Myocardial Infarction | 3 | Not yet recruiting | Oct 22, 2030 | 10,000 |
How it is read
Names in the registry
- “Pacibekitug”, 1 entry
Codes read as this program: PAC001.
Conditions, from the studies’ own filings
- Myocardial Infarction, 1 study
First seen by our ledger Nov 16, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.